1. Home
  2. ULS vs EXAS Comparison

ULS vs EXAS Comparison

Compare ULS & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo UL Solutions Inc.

ULS

UL Solutions Inc.

HOLD

Current Price

$80.23

Market Cap

15.4B

Sector

N/A

ML Signal

HOLD

Logo Exact Sciences Corporation

EXAS

Exact Sciences Corporation

HOLD

Current Price

$101.91

Market Cap

19.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ULS
EXAS
Founded
1894
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.4B
19.3B
IPO Year
2024
N/A

Fundamental Metrics

Financial Performance
Metric
ULS
EXAS
Price
$80.23
$101.91
Analyst Decision
Buy
Buy
Analyst Count
8
20
Target Price
$81.75
$77.94
AVG Volume (30 Days)
2.4M
4.9M
Earning Date
02-19-2026
02-18-2026
Dividend Yield
0.64%
N/A
EPS Growth
10.58
N/A
EPS
1.67
N/A
Revenue
$3,003,000,000.00
$3,082,033,000.00
Revenue This Year
$7.18
$19.40
Revenue Next Year
$5.56
$13.51
P/E Ratio
$48.41
N/A
Revenue Growth
6.68
14.47
52 Week Low
$48.54
$38.81
52 Week High
$91.95
$102.66

Technical Indicators

Market Signals
Indicator
ULS
EXAS
Relative Strength Index (RSI) 49.84 85.29
Support Level $76.63 $101.45
Resistance Level $80.62 $102.00
Average True Range (ATR) 1.65 0.39
MACD 0.31 -1.26
Stochastic Oscillator 74.76 88.69

Price Performance

Historical Comparison
ULS
EXAS

About ULS UL Solutions Inc.

UL Solutions is a global leader specializing in a broad range of product testing, inspection, and certification services. UL Solutions is the for-profit branch out of three organizations under the UL Enterprise. TIC operations make up nearly all of UL Solutions' total revenue and are composed of two segments: industrial and consumer. UL Solutions' remaining business includes software and advisory, which complements its core TIC offerings. The firm operates globally.

About EXAS Exact Sciences Corporation

Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.

Share on Social Networks: